{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:03:04Z","timestamp":1789448584267,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>As psychedelic interventions move from controlled clinical trials into broader implementation, critical dimensions of lived experience among patients, trial participants, families, and caregivers remain systematically undermeasured in research, service design, and oversight. The resulting gap between protocol-defined outcomes and real-world experiences over time creates blind spots in current approaches, particularly regarding safety, care quality, post-treatment stabilization, aftercare, and long-term vulnerability. I argue that lived experience is a form of systems-relevant evidence essential to strengthening decision-making and institutional accountability. I propose a public health framework for integrating lived experience and expertise into psychedelic research, care models, and governance. Integrating these forms of experiential knowledge can enhance outcome visibility beyond standard clinical measures and adverse event reporting by identifying both beneficial changes and emerging risks across care pathways that might otherwise remain obscured. Finally, I outline key implications for program evaluation, workforce development, and policy design. A rigorous psychedelic public health strategy requires stronger mechanisms for understanding safety and long-term efficacy to ensure that implementation both optimizes outcomes and provides accountability and protection.<\/jats:p>","DOI":"10.3389\/fpubh.2026.1951513","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:28:03Z","timestamp":1789446483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lived experience as systems-relevant evidence in psychedelic public health"],"prefix":"10.3389","volume":"14","author":[{"given":"Pedram","family":"Dara","sequence":"first","affiliation":[{"name":"Psychedelic Lived Experiences","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"117134","DOI":"10.1016\/j.socscimed.2024.117134","article-title":"Psychedelic public health: state of the field and implications for equity","volume":"357","author":"Kuiper","year":"2024","journal-title":"Soc Sci Med"},{"key":"ref2","article-title":"Psychedelic drugs: considerations for clinical investigations. Guidance for industry","year":"2026"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"115886","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"20451253231198466","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","article-title":"Psychedelic integration: an analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front Psychol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international Delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1114725","DOI":"10.3389\/fpsyt.2023.1114725","article-title":"Epistemic injustice and mental health research: a pragmatic approach to working with lived experience expertise","volume":"14","author":"Okoroji","year":"2023","journal-title":"Front Psych"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11019-014-9560-2","article-title":"Epistemic injustice in healthcare: a philosophical analysis","volume":"17","author":"Carel","year":"2014","journal-title":"Med Health Care Philos"},{"key":"ref10","volume-title":"FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making","year":"2025"},{"key":"ref11","volume-title":"WHO Framework for Meaningful Engagement of People Living with Noncommunicable Diseases, and Mental Health and Neurological Conditions","year":"2023"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","article-title":"Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies","volume":"34","author":"Breeksema","year":"2020","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","article-title":"Extended difficulties following the use of psychedelic drugs: a mixed methods study","volume":"18","author":"Evans","year":"2023","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"15998","DOI":"10.1038\/s41598-023-41145-x","article-title":"Case analysis of long-term negative psychological responses to psychedelics","volume":"13","author":"Bremler","year":"2023","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review","volume":"36","author":"Breeksema","year":"2022","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1192\/bjo.2025.10847","article-title":"Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review","volume":"11","author":"Marinis","year":"2025","journal-title":"BJPsych Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0322501","DOI":"10.1371\/journal.pone.0322501","article-title":"Navigating groundlessness: an interview study on dealing with ontological shock and existential distress following psychedelic experiences","volume":"20","author":"Argyri","year":"2025","journal-title":"PLoS One"},{"key":"ref20","volume-title":"ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3). Final Version","year":"2026"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13034-025-00930-4","article-title":"Leveraging family and caregiver support in psychedelic-assisted therapy: considerations for the treatment of adolescents","volume":"19","author":"Forsberg","year":"2025","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/00221678261455500","article-title":"First-person psychopharmacology (1PPP): a new way forward for clinical trials","author":"Stupak","year":"2026","journal-title":"J Humanist Psychol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1017\/S2045796017000555","article-title":"Research on a \u2018drug-centred\u2019 approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs","volume":"27","author":"Moncrieff","year":"2018","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"112170","DOI":"10.1016\/j.jclinepi.2026.112170","article-title":"Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin","volume":"192","author":"\u017duljevi\u0107","year":"2026","journal-title":"J Clin Epidemiol"},{"key":"ref25","volume-title":"Embedding Measures that Matter into Mental Health Systems: a Lived Experience-Informed Measurement Framework for Serious Mental Illness and Guidance for Future Initiatives","author":"Seidman","year":"2025"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1556\/2054.2024.00420","article-title":"An investigation into the varieties of extended difficulties following psychedelic drug use: duration, severity and helpful coping strategies","volume":"9","author":"Robinson","year":"2025","journal-title":"J Psychedelic Stud"},{"key":"ref27","volume-title":"Framework for Action on Interprofessional Education and Collaborative Practice","year":"2010"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/13561820.2021.2014796","article-title":"Peer support workers\u2019 role and expertise and interprofessional learning in mental health care: a scoping review","volume":"36","author":"Viking","year":"2022","journal-title":"J Interprof Care"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/bmjqs-2015-004839","article-title":"From tokenism to empowerment: progressing patient and public involvement in healthcare improvement","volume":"25","author":"Ocloo","year":"2016","journal-title":"BMJ Qual Saf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/0277-9536(95)00127-S","article-title":"What is participatory research?","volume":"41","author":"Cornwall","year":"1995","journal-title":"Soc Sci Med"},{"key":"ref31","volume-title":"Transforming Mental Health Through Lived Experience: Roadmap for Integrating Lived and Living Experience Practitioners Into Policy, Services and Community","year":"2025"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/15265161.2024.2342764","article-title":"The Hopkins-Oxford psychedelics ethics (HOPE) working group consensus statement","volume":"24","author":"Jacobs","year":"2024","journal-title":"Am J Bioeth"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1556\/2054.2019.018","article-title":"Making psychedelics into medicines: the politics and paradoxes of medicalization","volume":"4","author":"Noorani","year":"2020","journal-title":"J Psychedelic Stud"},{"key":"ref34","volume-title":"Complete Response, NDA 215455","year":"2024"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1951513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:28:05Z","timestamp":1789446485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1951513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2026.1951513"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1951513","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1951513"}}